


Mal-PEG8-Phe-Lys-PAB-Exatecan TFA

Cat. No.:	HY-148380A
Molecular Formula:	C ₇₅ H ₉₃ F ₄ N ₉ O ₂₂
Molecular Weight:	1548.58
Target:	Drug-Linker Conjugates for ADC; Topoisomerase
Pathway:	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (64.58 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.6458 mL	3.2288 mL	6.4575 mL
	5 mM	0.1292 mL	0.6458 mL	1.2915 mL
	10 mM	0.0646 mL	0.3229 mL	0.6458 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631)^[1].

IC₅₀ & Target

Camptothecins

REFERENCES

[1]. Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.

[2]. Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA